| 2024-02-05 |
停牌提示：
2024-02-05 06:44:08 停牌:
停牌原因 ▼▲
- 原因：
- Halt - Regulatory Concern_x000D_
Trading is halted in conjunction with another exchange or market for regulatory reasons.
|
| 2023-11-13 |
详情>>
股本变动：
变动后总股本540.65万股
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-161.33美元,归母净利润-4.29亿美元,同比去年增长-629%
|
| 2023-11-09 |
财报披露：
美东时间 2023-11-09 盘后发布财报
|
| 2023-11-02 |
详情>>
拆分方案：
每100.0000合并分成1.0000股
|
| 2023-10-16 |
股东大会：
将于2023-11-02召开股东大会
会议内容 ▼▲
- 1.Amendment to the company’s certificate of incorporation to effect the reverse stock split.
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-0.66美元,归母净利润-1.69亿美元,同比去年增长-3514.44%
|
| 2023-05-22 |
股东大会：
将于2023-06-15召开股东大会
会议内容 ▼▲
- 1.To elect the two Class II director nominees named in the proxy statement, each to serve on our Board of Directors (the “Board”) for a 3-year term and until their respective successors are duly elected and qualified;
2.To hold an advisory, non-binding vote regarding the compensation of our named executive officers for the 2022 fiscal year;
3.To vote on an amendment to the Company’s Certificate of Incorporation (as amended from time to time, the “Certificate of Incorporation”) to effect (a) a reverse stock split of our authorized, including both issued and outstanding and unissued, (i) Class A common stock, par value $0.0001 per share (the “Class A common stock”), at a ratio of 1-to-15, and (ii) Class B common stock, par value $0.0001 per share (the “Class B common stock” and, together with our Class A common stock, the “common stock”), at a ratio of 1-to-15, with the Board having the right to adjust each such ratio, acting in its sole discretion and in the Company’s best interest, down to 1-to-5 and up to 1-to-30, inclusive (the “Reverse Split Ratio”), and (b) an adjustment to the par value of the common stock such that the par value of the respective class equals their current par value divided by the Reverse Split Ratio (the “Reverse Stock Split”), without further approval or authorization of the Company’s stockholders, during a period of time not to exceed the 1-year anniversary of the date on which the Reverse Stock Split is approved by the Company’s stockholders at the Annual Meeting, subject to the Board’s authority to abandon the Reverse Stock Split at any time or to delay or postpone it;
4.To ratify the Audit Committee’s appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023;
5.To transact other business as may properly come before the meeting or any adjournment of the meeting.
|
| 2023-05-09 |
详情>>
业绩披露：
2023年一季报每股收益-0.12美元,归母净利润-2815万美元,同比去年增长-4365.15%
|
| 2023-03-15 |
详情>>
业绩披露：
2022年年报每股收益-0.95美元,归母净利润-2.07亿美元,同比去年增长-1050.23%
|
| 2023-03-15 |
详情>>
业绩披露：
2020年年报每股收益0.00美元,归母净利润-7106.4万美元,同比去年增长-259.27%
|
| 2022-11-09 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.28美元,归母净利润-5890.1万美元,同比去年增长-1050.41%
|
| 2022-08-09 |
详情>>
业绩披露：
2022年中报每股收益-0.02美元,归母净利润-467.3万美元,同比去年增长-202.59%
|
| 2022-08-09 |
详情>>
业绩披露：
2021年中报每股收益0.03美元,归母净利润455.50万美元,同比去年增长134.58%
|
| 2022-05-09 |
详情>>
业绩披露：
2022年一季报每股收益0.00美元,归母净利润66.00万美元,同比去年增长104.10%
|
| 2022-04-06 |
股东大会：
将于2022-05-16召开股东大会
会议内容 ▼▲
- 1.to elect the three Class I director nominees named in the proxy statement, each to serve on our Board of Directors (the “Board”) for a three-year term and until their respective successors are duly elected and qualified;
2.to hold an advisory vote regarding the compensation of our named executive officers for the 2022 fiscal year;
3.to hold an advisory vote on whether an advisory vote on executive compensation should be held every one, two or three years;
4.to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022;
5.to transact other business as may properly come before the meeting or any adjournment of the meeting.
|
| 2022-03-14 |
详情>>
业绩披露：
2021年年报每股收益-0.11美元,归母净利润-1802万美元,同比去年增长74.64%
|
| 2021-11-10 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.03美元,归母净利润-512万美元,同比去年增长78.92%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-06-04 |
详情>>
内部人交易：
Jaws Sponsor LLC等共交易2笔
|
| 2021-05-07 |
股东大会：
将于2021-06-02召开股东大会
会议内容 ▼▲
- 1.to consider and vote upon a proposal, which is referred to herein as the “Business Combination Proposal,” to approve and adopt the Business Combination Agreement, dated effective as of November 11, 2020 (as may be further amended or supplemented from time to time, the “Business Combination Agreement”), by and among Jaws, Jaws Merger Sub, LLC (“Merger Sub”), Primary Care (ITC) Holdings, LLC (“Seller”) and Primary Care (ITC) Intermediate Holdings, LLC (“PCIH”), a copy of which is attached to the accompanying proxy statement/prospectus as Annex A, and the transactions contemplated thereby. In accordance with the terms and subject to the conditions of the Business Combination Agreement, among other things, following the Domestication of Jaws to the State of Delaware as described below, Jaws will acquire certain equity interests of PCIH from Seller, its sole member, by way of its wholly-owned subsidiary, Merger Sub, merging with and into PCIH, and becoming a direct subsidiary of the Company as a result thereof (the “Business Combination”). As a condition to closing the Business Combination, the board of directors of Jaws has unanimously approved, and shareholders of Jaws are being asked to consider and vote upon a proposal to approve (the “Domestication Proposal”), a change of Jaws’ jurisdiction of incorporation by deregistering as an exempted company in the Cayman Islands and transferring by way of continuation and domesticating as a corporation incorporated under the laws of the State of Delaware (the “Domestication”). As used herein, the “Company” refers to Jaws as a Delaware corporation by way of continuation following the Domestication and the Business Combination, which, in connection with the Domestication and simultaneously with the consummation of the Business Combination, will change its corporate name to “Cano Health, Inc.”
|